Generic Portal

— Research Explorer

SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

Research output: Contribution to journal › Article › Academic › peer-review

DOI

https://doi.org/10.3389/fphar.2022.1042989
Final published version

Evelien G. E. Hurkmans
Jan B. Koenderink
Jeroen J. M. W. van den Heuvel
Yvonne M. H. Versleijen-Jonkers
Melissa H. S. Hillebrandt-Roeffen
Johanne M. Groothuismink
Hanneke I. Vos
Winette T. A. van der Graaf
Uta Flucke
Grigor Muradjan
Hendrik W. B. Schreuder
Melanie M. Hagleitner
Han G. Brunner
Hans Gelderblom
Anne-Marie Cleton-Jansen
Henk-Jan Guchelaar
Eveline S. J. M. de Bont
Daan J. Touw
G. Jan Nijhoff
Rachael Windsor
Ana Patiño-García
Anna González-Neira
Federica Saletta
Geoff McCowage
Sumanth Nagabushan
Daniel Catchpoole
D. Maroeska W. M. te Loo
Marieke J. H. Coenen

Original language	English
Article number	1042989
Journal	Frontiers in pharmacology
Volume	13
DOIs	https://doi.org/10.3389/fphar.2022.1042989
Publication status	Published - 9 Nov 2022

Research areas

L-type amino acid transporter 2, doxorubicin, early disease progression, osteosarcoma, pharmacogenetics

ID: 27973310